IL281081B - A method to generate fibroblast and fibroblastic mass positive for g-csf - Google Patents

A method to generate fibroblast and fibroblastic mass positive for g-csf

Info

Publication number
IL281081B
IL281081B IL281081A IL28108121A IL281081B IL 281081 B IL281081 B IL 281081B IL 281081 A IL281081 A IL 281081A IL 28108121 A IL28108121 A IL 28108121A IL 281081 B IL281081 B IL 281081B
Authority
IL
Israel
Prior art keywords
fibroblasts
positive
hcf
cells
csf
Prior art date
Application number
IL281081A
Other languages
English (en)
Hebrew (he)
Other versions
IL281081A (en
Inventor
Takahiro Iwamiya
Tomoyuki Osugi
Masaya Suzuki
Original Assignee
Metcela Inc
Takahiro Iwamiya
Tomoyuki Osugi
Masaya Suzuki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metcela Inc, Takahiro Iwamiya, Tomoyuki Osugi, Masaya Suzuki filed Critical Metcela Inc
Publication of IL281081A publication Critical patent/IL281081A/en
Publication of IL281081B publication Critical patent/IL281081B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Vascular Medicine (AREA)
IL281081A 2018-08-29 2019-08-29 A method to generate fibroblast and fibroblastic mass positive for g-csf IL281081B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018160898 2018-08-29
PCT/JP2019/033835 WO2020045547A1 (ja) 2018-08-29 2019-08-29 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団

Publications (2)

Publication Number Publication Date
IL281081A IL281081A (en) 2021-04-29
IL281081B true IL281081B (en) 2022-07-01

Family

ID=69642802

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281081A IL281081B (en) 2018-08-29 2019-08-29 A method to generate fibroblast and fibroblastic mass positive for g-csf

Country Status (10)

Country Link
US (1) US20210254009A1 (https=)
EP (1) EP3845635A4 (https=)
JP (2) JP6883904B2 (https=)
KR (1) KR102883773B1 (https=)
CN (1) CN112639082A (https=)
AU (1) AU2019332400B2 (https=)
CA (1) CA3110831A1 (https=)
IL (1) IL281081B (https=)
SG (1) SG11202102028SA (https=)
WO (1) WO2020045547A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3845635A4 (en) * 2018-08-29 2022-06-15 Metcela Inc. PROCEDURE FOR PREPARING FIBROBLAST AND G-CSF-POSITIVE FIBROBLAST MASS
WO2021177387A1 (ja) * 2020-03-04 2021-09-10 株式会社メトセラ エリスロポエチン産生能が亢進された線維芽細胞
CA3211113A1 (en) 2021-03-04 2022-09-09 Metcela Inc. Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same
US20240316113A1 (en) 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease
CN119685401A (zh) * 2024-06-03 2025-03-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种改造成纤维细胞的方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1886150B (zh) * 2003-10-27 2010-05-26 学校法人庆应义塾 含有g-csf的成纤维细胞动员剂及创伤治疗剂
US9987310B2 (en) * 2013-11-27 2018-06-05 University Of Louisville Research Foundation, Inc. Cardiac progenitor cells and methods of use therefor
CN106661552B (zh) * 2014-07-11 2020-07-07 玛土撤拉有限公司 心脏细胞培养材料
CN107881145A (zh) * 2016-09-26 2018-04-06 新乡医学院 一种分选大鼠心成纤维细胞cd90+亚群的方法及其应用
KR102407387B1 (ko) * 2017-02-24 2022-06-10 가부시키가이샤 메토세라 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법
EP3845635A4 (en) * 2018-08-29 2022-06-15 Metcela Inc. PROCEDURE FOR PREPARING FIBROBLAST AND G-CSF-POSITIVE FIBROBLAST MASS

Also Published As

Publication number Publication date
EP3845635A4 (en) 2022-06-15
IL281081A (en) 2021-04-29
CA3110831A1 (en) 2020-03-05
AU2019332400A1 (en) 2021-04-01
SG11202102028SA (en) 2021-03-30
JP2021118728A (ja) 2021-08-12
KR20210049892A (ko) 2021-05-06
EP3845635A1 (en) 2021-07-07
WO2020045547A1 (ja) 2020-03-05
KR102883773B1 (ko) 2025-11-07
JP6883904B2 (ja) 2021-06-09
AU2019332400B2 (en) 2025-06-26
CN112639082A (zh) 2021-04-09
JP7428389B2 (ja) 2024-02-06
JPWO2020045547A1 (ja) 2021-02-15
US20210254009A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
IL281081B (en) A method to generate fibroblast and fibroblastic mass positive for g-csf
Moghadasi et al. RETRACTED ARTICLE: a paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine
Cui et al. Bioinspired nanovesicles convert the skeletal endothelium-associated secretory phenotype to treat osteoporosis
Liu et al. Exosomes derived from stem cells from apical papilla promote craniofacial soft tissue regeneration by enhancing Cdc42-mediated vascularization
Guo et al. Transplantation of marrow-derived cardiac stem cells carried in fibrin improves cardiac function after myocardial infarction
US20210236598A1 (en) Methods for organ regeneration
CN105517587A (zh) 伤口愈合与组织工程
IL267958B2 (en) Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use
Twardowski et al. Cardiac fibroblasts support endothelial cell proliferation and sprout formation but not the development of multicellular sprouts in a fibrin gel co-culture model
Yokoyama et al. Human induced pluripotent stem cell-derived three-dimensional cardiomyocyte tissues ameliorate the rat ischemic myocardium by remodeling the extracellular matrix and cardiac protein phenotype
US20230374462A1 (en) Method for producing myocardial stem/progenitor cell and method for suppressing myocardial fibrosis
CN111417718A (zh) 由cd31阳性cd45阴性cd200阳性的哺乳动物细胞组成的细胞群及其应用
JP7233147B2 (ja) リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物
WO2022218443A1 (zh) 间充质干细胞来源的外泌体治疗脑卒中的方法和组合物
IL296125A (en) Fibroblasts have an increased ability to produce erythropoietin
RU2800644C2 (ru) Способ получения фибробластов и г-ксф-положительная фибробластная масса
Kang et al. Unveiling the role of GATA4 in endothelial cell senescence and atherosclerosis development
Xiang et al. Pulsed electromagnetic fields preconditioned extracellular vesicles derived from mesenchymal stromal cells prevents necroptosis of osteoblasts in osteonecrosis of the femoral head rats
WO2014098211A1 (ja) 組織再生促進剤
Li et al. Development of prevascularized cell sheets using single bone marrow mesenchymal stem cell source for tissue regeneration
TW202434720A (zh) 包含心臟內幹細胞的細胞集團
CN121136915A (zh) 富含蛋白酶体人胎盘源促血管干细胞外囊泡分离及其应用
Rodiers The neuroregenerative aspects of insulin-like growth factor-2 enhanced dental pulp stem cells as a therapy for ischemic stroke
WO2025106654A1 (en) Methods of vascular cell therapy and endothelial cell engraftment via mitophagy inducers
이주로 Therapeutic potential-enhanced mesenchymal stem cell-derived nanovesicles